Literature DB >> 33434571

Toxicant exposure during pregnancy increases protective proteins in the dam and a sexually dimorphic response in the fetus.

Alana L Rister1, Ciro M Amato2, Tara Nash3, Michael W McCoy2, Michael Bereman3, Krista A McCoy2.   

Abstract

Endocrine disrupting compounds (EDCs) are ubiquitous environmental pollutants that alter endocrine system function, induce birth defects, and a myriad of other negative health outcomes. Although the mechanism of toxicity of many EDCs have been studied in detail, little work has focused on understanding the mechanisms through which pregnant dams and fetuses protect themselves from EDCs, or if those protective mechanisms are sexually dimorphic in fetuses. In this study, we examined proteomic alterations in the livers of mouse dams and their male and female fetuses induced by vinclozolin, a model antiandrogenic EDC. Dam livers upregulated nine phase I and phase II detoxification pathways and pathway analysis revealed that more pathways are significantly enriched in dam livers than in fetal livers. Phase I and II detoxification proteins are also involved in steroid and steroid hormone biosynthesis and vinclozolin likely alters steroid levels in both the dam and the fetus. The response of the fetal liver proteome to vinclozolin exposure is sexually dimorphic. Female fetal livers upregulated proteins in xenobiotic metabolism pathways, whereas male fetal livers upregulated proteins in oxidative phosphorylation pathways. These results suggest that female fetuses increase protective mechanisms, whereas male fetuses increase ATP production and several disease pathways that are indicative of oxidative damage. Females fetuses upregulate proteins and protective pathways that were similar to the dams whereas males did not. If this sexually dimorphic pattern is typical, then males might generally be more sensitive to EDCs.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Detoxification; Endocrine Disrupting Compounds; Liver; Proteomics; Vinclozolin

Mesh:

Substances:

Year:  2021        PMID: 33434571      PMCID: PMC9152768          DOI: 10.1016/j.taap.2021.115407

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.460


  7 in total

1.  Identification of testosterone-/androgen receptor-regulated genes in mouse Sertoli cells.

Authors:  Qiao-Xia Zhang; Xiao-Yan Zhang; Zhen-Ming Zhang; Wei Lu; Ling Liu; Gang Li; Zhi-Ming Cai; Yao-Ting Gui; Chawnshang Chang
Journal:  Asian J Androl       Date:  2011-10-17       Impact factor: 3.285

Review 2.  Early-life Exposure to Endocrine Disrupting Chemicals and Later-life Health Outcomes: An Epigenetic Bridge?

Authors:  Alexander Vaiserman
Journal:  Aging Dis       Date:  2014-01-28       Impact factor: 6.745

3.  Effect of the anti-androgenic endocrine disruptor vinclozolin on embryonic testis cord formation and postnatal testis development and function.

Authors:  Mehmet Uzumcu; Hiroetsu Suzuki; Michael K Skinner
Journal:  Reprod Toxicol       Date:  2004 Aug-Sep       Impact factor: 3.143

Review 4.  Endocrine disruptors, genital development, and hypospadias.

Authors:  Ming-Hsien Wang; Laurence S Baskin
Journal:  J Androl       Date:  2008-05-22

5.  Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide.

Authors:  C Wong; W R Kelce; M Sar; E M Wilson
Journal:  J Biol Chem       Date:  1995-08-25       Impact factor: 5.157

6.  Reduced birth weight in relation to pesticide mixtures detected in cord blood of full-term infants.

Authors:  Erin L Wickerham; Betsy Lozoff; Jie Shao; Niko Kaciroti; Yankai Xia; John D Meeker
Journal:  Environ Int       Date:  2012-07-13       Impact factor: 9.621

7.  Sulforaphane Prevents Testicular Damage in Kunming Mice Exposed to Cadmium via Activation of Nrf2/ARE Signaling Pathways.

Authors:  Shu-Hua Yang; Miao Long; Li-Hui Yu; Lin Li; Peng Li; Yi Zhang; Yang Guo; Feng Gao; Ming-Da Liu; Jian-Bin He
Journal:  Int J Mol Sci       Date:  2016-10-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.